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Abstract
Purpose  and  objectives:  To  assess  the  effectiveness  of  percutaneous  vertebroplasty  (PV)  in
patients with  vertebral  collapse  due  to  metastases.
Materials  and  methods:  PV  procedures  performed  on  95  vertebras  in  52  patients  with  primary
malignancy  were  retrospectively  evaluated.  Vertebral  metastases,  primary  malignancies  of  the
patients,  pain  before  and  after  PV  on  a  visual  analogue  scale  (VAS),  amount  of  polymethyl-
methacrylate  (PMMA)  cement  applied  to  the  vertebral  body  during  PV,  PMMA  cement  leakage
and vertebral  approaches  were  evaluated.
Results:  VAS  scores  of  43  patients  (in  total  79  vertebras)  were  evaluated.  Median  VAS  scores
of patients  declined  from  8  (4—10)  before  PV  to  3  (0—7)  within  one  day  after  the  proce-
dure, to  2  (0—9)  one  week  after  the  procedure  and  eventually  to  2  (0—9)  3  months  after  the
 amount  applied  to  the  vertebral  body  during  PV  varied  betweenprocedure  (p  <  0.001).  PMMA
1.5—9 mL  (average  ±  SD  4.91  ±  1.61).  There  was  no  signiﬁcant  statistical  correlation  between
PMMA amounts  and  VAS  scores  within  one  day  after,  1  week  after  and  3  months  after  the  PV
procedure  (p  >  0.05).
∗ Corresponding author.
E-mail addresses: omerfatihnas@gmail.com (O.F. Nas), drinecikli@gmail.com (M.F. Inecikli), dremrekacar@yahoo.com (E. Kacar),
rbuyukkaya@gmail.com (R. Buyukkaya), ozkaya@uludag.edu.tr (G. Ozkaya), oaydindr@yahoo.com (O. Aydın), cerdogan@uludag.edu.tr
(C. Erdogan), bhakyemez@uludag.edu.tr (B. Hakyemez).
http://dx.doi.org/10.1016/j.diii.2015.05.001
2211-5684/© 2015 Éditions franc¸aises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
1162  O.F.  Nas  et  al.
Conclusion:  PV  is  a  simple,  effective,  reliable,  easy  to  perform  and  minimally  invasive  procedure
in patients  with  painful  vertebral  metastases.
© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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wetastatic  disease  of  a  primary  malignancy  is  most  com-
only  seen  in  the  skeletal  system  after  lungs  and  liver,  and
ertebras  are  the  most  commonly  involved  bones  [1,2].  Pain
s  an  important  symptom  in  patients  with  spinal  metastasis.
rogression  of  spinal  metastasis  can  result  in  compression
f  the  spinal  column  caused  by  fracture  of  vertebral  bodies
3].
Percutaneous  vertebroplasty  (PV)  is  a  minimally  inva-
ive  procedure  with  polymethylmethacrylate  (PMMA)  bone
ement  injection  into  the  vertebral  body  [4].  It  is  one  of
he  modalities  accepted  for  treating  vertebral  fractures
aused  by  osteoporosis,  malignancies  and  trauma  [5].  PV
as  ﬁrst  described  in  1987  by  Galibert  et  al.  in  treatment
f  a  painful  vertebral  hemangioma  [6].  Two  main  indica-
ions  of  PV  in  spinal  metastasis  treatment  are  analgesia  and
ertebral  column  stabilization  [7].  The  superiority  of  PV  in
alignant  spinal  involvement  is  that  it  is  less  invasive  than
pen  surgery  and  faster  in  relieving  pain  than  radiotherapy
nd  other  conventional  treatment  methods  [5].  PV  effects
ccur  quickly  and  it  is  a  supplementary  procedure  to  radio-
herapy  or  chemotherapy  in  patients  with  malignant  spinal
nvolvement  [8].  Balloon  kyphoplasty  (BK),  radiofrequency
RF)  kyphoplasty  and  plasma-mediated  radiofrequency  abla-
ion  (coblation)  can  be  used  to  treat  vertebral  fractures  in
ddition  to  PV.  Bone  metastases  can  also  be  treated  with
ercutaneous  ablation  [9].
From  our  study,  outcomes  of  PV  procedures  performed
n  our  department  on  patients  with  vertebral  metastasis
nd  known  primary  malignancies  over  a  six-year  period  are
resented.  The  purpose  of  our  study  was  to  assess  the  effec-
iveness  of  PV  in  patients  with  vertebral  collapse  due  to
etastases.
aterials and methods
rotocol
V  procedures  performed  on  95  vertebras  in  52  patients  with
rimary  malignancy  between  April  2008  and  April  2014  were
etrospectively  evaluated.  The  only  indication  of  vertebro-
lasty  was  severe  back  pain,  and  this  pain  generally  limited
ody  movements  of  patients  and  was  unresponsive  to  dif-
erent  painkillers.  Most  of  our  patients  were  using  level  3
moderate  to  severe  pain)  painkillers.  Magnetic  resonance
MR)  imaging  was  performed  on  all  patients  before  the
rocedure,  in  order  to  assess  the  localization  of  vertebral
etastasis  and  the  extent  of  tumoral  inﬁltration  into  the
pinal  canal  and  paravertebral  tissue.  Conventional  sagittal
o
P
a
s1-weighted,  T2-weighted  and  STIR  images  were  acquired
n  a 3  T  (Achieva  TX,  Philips,  Best,  Netherlands)  or  a  1.5  T
canner  (Magnetom  Vision  plus,  Siemens,  Erlangen,  Ger-
any)  using  a  spine  coil.  Sagittal  post-contrast  T1-weighted
mages  were  acquired  after  administration  of  0.1  mmol/kg
R  contrast  media  when  necessary.  The  MR  sequence  param-
ters  used  are  indicated  in  Table  1.  Metastatic  involvement
f  the  vertebras  was  detected  clinically  and  radiologi-
ally  in  patients  with  known  primary  malignancies.  Twelve
f  52  patients  were  treated  with  chemotherapy,  2  with
adiotherapy  and  38  with  both  therapies  before  or  after
he  procedure.  Biopsies  were  performed  on  vertebras  with
uspicious  metastatic  ﬁndings.  The  extent  of  metastatic
nvolvement  in  vertebral  bodies  was  assessed  using  the
emi-quantitative  visual  assessment  index  showing  vertebral
eformity  developed  by  Genant  et  al.  [10].  In  this  index,
eight  loss  in  the  anterior,  middle  and/or  posterior  columns
f  a  vertebral  body  is  deﬁned  as,  grade  0:  normal,  grade
:  20—25%  mild,  grade  2:  25—40%  moderate,  grade  3:  >  40%
evere.  Our  study  was  approved  by  the  ethical  committee.
perative technique
V  was  performed  with  sterile  conditions,  under  sedoanal-
esia  (midazolam  0.03  mg/kg  i.v.  and/or  fentanyl  1  /kg  i.v.
nd/or  ketamine  1  mg/kg  i.v.  or  propophol  3—5  mg/kg  i.v.
nd/or  pethidine  1  mg/kg  i.m.),  in  a  biplane,  ﬂat-paneled
ngiography  unit  (AXIOM  Artis  FD  Biplane  Angiosuite,
iemens  Medical  Solutions,  Erlangen,  Germany).  Ampicillin
000  mg-sulbactam  500  mg  combination  was  administered
.v.  before  the  procedure  for  antibioprophylaxis.  Patients
aid  down  on  the  angiography  table  in  prone  position.  During
he  procedure,  11,  13  or  14  gauge  single  use  only  bone  biopsy
eedles  were  used.  Biopsy  needles  were  placed  into  the
ertebral  body  through  the  vertebral  pedicle  with  the  guid-
nce  of  anteroposterior  and/or  lateral  ﬂuoroscopic  imaging.
eft  transpedicular,  right  transpedicular  and  bipedicular
pproaches  were  used  to  reach  the  vertebral  bodies.  Biop-
ies  were  performed  on  vertebras  with  suspicious  metastatic
ndings.  PMMA  (Cemento  Fixx,  Optimed,  San  Possidonio,
taly)  bone  cement  was  applied  to  the  vertebral  body  under
uoroscopy  in  a  slow  and  controlled  way  manually  or  using
n  injection  gun.  The  cement  was  applied  preferentially  to
he  lytic  zone  of  the  vertebra.  No  rupture  in  the  posterior
all  of  the  vertebral  body  was  observed.  PV  was  performed
n  2,  3  or  even  4  or  5  vertebral  levels  in  the  same  session.
atients  were  followed  in  the  observation  room  for  3  hours
fter  the  procedure  and  consequently  discharged  within  the
ame  day.
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Table  1  MR  sequence  parameters.
Sequences  MR  (T)  TR  (ms)  TE  (ms)  TI  (ms)  Matrix  NSA  Slice
thickness
(mm)
Slice  gap
(mm)
FOV  Time  (s)
Sagittal  T2-
weighted
3 3500  110  —  200  ×  286  2  4  0.4  300  ×  160  190
1.5 4200  90  —  192  ×  512  2  3  0.3  340  ×  200  150
Sagittal  T1-
weighted
3 460  8  —  200  ×  300  2  4  0.4  300  ×  160  110
1.5  550  15  —  192  ×  256  2  3  0.3  340  ×  200  180
Sagittal
STIR
3  3000  80  210  124  ×  169  2  4  0.4  300  ×  160  160
1.5  4000  90  160  192  ×  512  3  3  0.3  340  ×  200  210
STIR: short tau inversion recovery; MR: magnetic resonance; TR: time to repetition; TE: time to echo; TI: inversion time; NSA: number
of signal averages; FOV: ﬁeld of view; T: Tesla; mm: millimeter; ms: millisecond; s: second.
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bPain assessment
Visual  analogue  scale  (VAS)  was  used  to  assess  patients’  pain
scores  the  day  before,  within  one  day  after,  1  week  and
3  months  after  the  procedure.  VAS  involves  the  standard
pain  scale  from  0  to  10  (0  =  no  pain,  10  =  intolerable,  the
most  severe  pain  ever  felt  in  a  patient’s  life)  in  order  to
determine  the  level  of  pain  objectively.  VAS  scores  of  the
patients  were  assessed  by  talking  face  to  face  or  by  phone
calls  before,  within  one  day  after,  1  week  and  3  months  after
the  procedure.
Statistical analysis
All  statistical  analyses  were  performed  with  the  SPSS  22.01
statistical  package  program.  Descriptive  values  of  variables
are  expressed  as  means  ±  standard  deviation  or  medians
(minimum-maximum).  Shapiro-Wilk  Test  was  used  to  deter-
mine  the  normal  distribution  of  data.  Wilcoxon  Signed  Rank
Test  was  used  for  group  comparisons.  Relationships  between
variables  were  reviewed  using  Spearman’s  Rank  Correla-
tion  Coefﬁcient.  The  levels  of  signiﬁcance  were  deﬁned  as
  =  0.05.
Results
In  total,  52  patients  (24  men  [46.2%]  and  28  women
[53.8%],  age  range:  21—86  years  [mean  63.98  ±  12.97])  were
enrolled.  The  primary  tumor  locations  in  descending  order
of  frequency  were  the  breast  (n  =  14/52;  [26.9%]),  lung
(n  =  9/52;  [17.3%]),  prostate  (n  =  7/52;  [13.5%]),  kidney
(n  =  5/52;  [9.6%]),  stomach  (n  =  5/52;  [9.6%])  and  others
(n  =  12/52;  [23.1%]).  Others  were  malignancies  like  colon,
lymphoma,  pancreas  and  larynx.  Biopsy  was  performed
during  the  procedure  on  15  (n  =  15/95;  [15.8%])  vertebras
with  certain  primary  malignancy  but  suspicious  metastases.
Metastatic  carcinoma  was  detected  in  6  (n  =  6/95;  [6.3%])
and  non-speciﬁc  ﬁndings  such  as  blood  elements,  ﬁbrin  and
trabecular  particles  were  detected  in  9  (n  =  9/95;  [9.5%])  of
these  vertebras.
(
b
i
3PV  was  performed  on  95  vertebras  (54  lumbar  [56.8%]
nd  41  thoracic  [43.2%]).  PV  was  most  frequently  performed
t  the  L1  level  (n  =  17/95;  [17.9%])  for  lumbar  and  at  the
12  level  (n  =  13/95;  [13.7%])  for  thoracic  vertebras.  A  sin-
le  vertebra  was  involved  in  25  patients  (n  =  25/52;  [48%])
nd  more  than  one  vertebras  were  involved  in  27  patients
n  =  27/52;  [52%])  (in  15  patients:  2,  in  9  patients:  3,  in
 patients:  4,  and  in  1  patient:  5).  According  to  the  semi-
uantitative  visual  assessment  index  developed  by  Genant
t  al.  [8],  height  losses  of  vertebras  were  grade  0:  7
n  =  7/95;  [7.4%]),  grade  1:  30  (n  =  30/95;  [31.6%]),  grade  2:
1  (n  =  31/95;  [32.6%])  and  grade  3:  27  (n  =  27/95;  [28.4%]).
eft  transpedicular  (n  =  63/95;  [66.3%]),  right  transpedic-
lar  (n  =  7/95;  [7.4%])  and  bipedicular  (n  =  25/95;  [26.3%])
pproaches  were  used  for  PV  procedures.
The  efﬁcacy  of  percutaneous  vertebroplasty  was  assessed
y  considering  VAS  scores  before  and  after  PV,  PMMA  amount
pplied  to  the  vertebral  body  and  PMMA  leakage.
The  PV  procedure  was  performed  on  95  vertebras  in  52
atients.  Nine  patients  could  not  be  reached  by  phone.  VAS
cores  of  79  vertebras  in  43  patients  were  assessed.  Median
AS  scores  of  patients  declined  from  8  (4—10)  before  PV
o  3  (0—7)  within  one  day  after,  to  2  (0—9)  1  week  after
nd  eventually  to  2  (0—9)  3  months  after  the  procedure
p  <  0.001)  (Fig.  1).  There  was  a  signiﬁcant  statistical  differ-
nce  between  average  VAS  scores  within  one  day  after,  and
 week  after  the  procedure  (p  <  0.001);  within  one  day  after
nd  3  months  after  the  procedure  (p  <  0.001);  and  1  week
fter  and  3  months  after  the  procedure  (p  =  0.002).
PMMA  amount  applied  to  the  vertebral  body  varied
etween  1.5  and  9  mL  (average  ±  SD  4.91  ±  1.61).  There  was
o  signiﬁcant  statistical  correlation  between  PMMA  amounts
nd  VAS  scores  within  one  day  after,  1  week  after  and
 months  after  the  procedure  (p  > 0.05).
No  complication  was  observed  in  52  vertebras  (n  =  52/95;
54.7%]).  PMMA  leakage  was  present  in  a  total  of  43  verte-
ras  (n  =  43/95;  [45.3%])  (intradiscal  leakage  in  20  vertebras
n  =  20/95;  [21.1%]),  leakage  into  the  epidural  or  paraverte-
ral  veins  in  20  vertebras  (n  =  20/95;  [21.1%])  and  leakage
nto  both  disc  and  the  epidural  or  paravertebral  veins  in
 vertebras  (n  =  3/95;  [3.1%]).  No  neurological  deﬁcits  or
1164  O.F.  Nas  et  al.
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Table  2  Assessment  of  52  patients  with  primary  malig-
nancy  who  had  the  PV  procedure.
Sex  (men/women)  24/28
Average  age  63.98  ±  12.97  (21—86)
Median  VAS  score  before  PV  8  (4—10)
Median  VAS  score  within  one
day  after  PV
3 (0—7)
Median  VAS  score  1  week
after  PV
2  (0—9)
Median  VAS  score  3  months
after  PV
2  (0—9)
Primary  malignancy  52
Breast  14/52
Lungs  9/52
Prostate  7/52
Renal  5/52
Stomach  5/52
Others  12/52
Localization  95
Thoracic  41/95
T6  2/95
T7  5/95
T8  4/95
T9  2/95
T10  8/95
T11  7/95
T12  13/95
Lumbar  54/95
L1  17/95
L2  13/95
L3  8/95
L4  8/95
L5  8/95
PV  approaches  95
Left  transpedicular  63/95
Right  transpedicular  7/95
Bipedicular  25/95
Vertebral  loss  of  height  95
Grade  0  7/95
Grade  1  30/95
Grade  2  31/95
Grade  3 27/95
Complications  on  vertebral
level
43/95
Leaks  into  the  disc  20/95
Leaks  into  the  epidural  or
paravertebral  vein
20/95
Leaks  into  the  disc  and
epidural  or  paravertebral
vein
3/95igure 1. VAS scores before, within one day after, 1 week after
nd 3 months after the PV procedure (median min—max).
linical  symptoms  were  observed  as  a  result  of  this  leak-
ge.
Table  2 shows  the  detailed  analysis  of  52  patients  and
heir  primary  malignancies.  Case  examples  are  shown  in
igs.  2  and  3.
iscussion
his  study  demonstrates  that  PV  decreases  the  pain  of
atients  with  vertebral  metastases  who  have  excessive  pain
nd/or  surgery  has  great  risks.  Vertebral  metastasis  is  often
symptomatic,  but  it  can  become  symptomatic  due  to  ver-
ebral  destruction  caused  by  pathological  fractures  resulting
n  development  of  spinal  instability  and  neural  compression.
t  has  been  proven  that  chemotherapy,  radiotherapy  and
ormonal  treatments  reduce  osteolytic  destruction  and  neu-
ological  damage.  But  these  treatment  modalities  may  not
elp  with  spinal  stability,  cord  compression  and  pain  reduc-
ion.  Surgery  can  help  with  spinal  stability,  cord  compression
nd  pain  reduction  but  it  presents  great  risks  for  critical
atients  [11].
PV  is  a  minimally  invasive  procedure  where  PMMA  bone
ement  is  injected  into  the  vertebral  body  to  treat  the  pain
ue  to  a  vertebral  compression  fracture.  Cement  provides
tructural  stabilization  and  a  pain  reduction  effect  in  the
ertebral  body  [12].  The  main  indication  for  PV  in  metastatic
atients  is  to  control  local  pain  [13].  It  can  also  be  used
o  stabilize  bones  having  lytic  metastases  and  high  fracture
isk  [14].  Weill  et  al.  [15]  succeeded  in  reducing  pain  in  24
ut  of  33  procedures  in  spinal  metastasis  patients  using  PV.
ikami  et  al.  [13]  state  that  the  preoperative  mean  VAS
core  was  reduced  from  7.3  to  postoperative  1.9  with  PV
erformed  on  141  metastatic  vertebras  of  69  patients.  Tseng
t  al.  [4]  showed  that  the  preoperative  mean  VAS  score  of  8.1
ecreased  to  3.8  one  day  after  and  to  2.8  six  months  after
V.  Alvarez  et  al.  [11]  reported  that  the  preoperative  VAS
core  of  9.1  decreased  to  3.2  immediately  after  and  to  2.8
hree  months  after  PV.  Barragán-Campos  et  al.  observed  a
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Figure 2. Hypointense metastatic involvement on sagittal T1-weighted image on L3 vertebral body (large arrow) (a) and hyperintense
metastatic involvement on STIR sagittal image (large arrow) (b) in a 45-year-old woman with primary breast malignancy before PV. Increase
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ain metabolic activity on L3 vertebral body is shown on bone scinti
L3-L4 disc and left paravertebral vein after PV (e, f).
signiﬁcant  decrease  in  VAS  scores  of  patients  with  vertebral
metastases  of  breast  cancer  [16].  In  our  department,  median
VAS  scores  of  79  metastatic  vertebras  of  43  patients  with
primary  malignancy  was  8  before,  3  within  one  day  after,
2  after  1  week  and  2  three  months  after  the  procedure.  In
our  study,  the  decreases  in  VAS  scores  after  the  procedure
was  consistent  with  the  literature  data.  PV  provides  a  quick
relief  of  pain  in  patients  with  vertebral  metastasis.
PMMA  cement  prevents  the  collapse  of  vertebra  by
strengthening  the  vertebral  body  [7].  PMMA  causes  damage
to  nerve  endings  and  cytotoxic  effects  because  of  its  heat
releasing  effect  during  polymerization  [7,17].  Decrease  in
tumor  progression  or  recurrence  can  be  obtained  from  the
antitumoral  effect  of  the  cement  [18].  In  order  to  achieve
vertebral  stiffness  after  PV,  an  average  of  3.5  mL  volume
of  PMMA  is  sufﬁcient  [4,19].  To  achieve  vertebral  stiffness
m
o
cy scan (small arrow) (c, d). PMMA bone cement leakage into the
fter  PV,  Tseng  et  al.  used  [4]  5.16  ±  1.63  mL,  Chew  et  al.
5]  used  less  than  5  mL,  and  Barragán-Campos  et  al.  [7]
sed  4.7  ±  1.55  mL  of  PMMA.  The  average  PMMA  amount  used
n  our  study  to  achieve  sufﬁcient  vertebral  stiffness  was
.91  ±  1.61  mL  and  was  similar  to  what  was  used  in  other
tudies.  In  addition,  there  was  no  signiﬁcant  correlation
etween  PMMA  amount  and  VAS  scores.
Serious  complications  of  PV  are  rare  [12,20,21].  Seri-
us  complications  have  been  reported  in  approximately
.1—1.3%  of  published  cases  [21].  Small  leakage  of  PMMA
nto  the  pulmonary  vessels  through  epidural  or  paraverte-
ral  veins  is  usually  clinically  insigniﬁcant.  However,  there
re  reported  cases  of  pulmonary  embolism  [7,20,22,23].  The
ain  reason  for  complications  is  believed  to  be  the  leakage
f  PMMA.  The  incidence  of  symptomatic  and  asymptomatic
ement  leakage  varies  from  2  to  73%  [13],  but  Mousavi  et  al.
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Figure 3. Hypointense metastatic involvement on sagittal T1-weighted image on L3 vertebral body (large arrow) (a) and hyperintense
m  a 63
s psy a
f
c
a
l
c
P
b
4
o
f
m
o
s
b
l
b
p
c
q
q
f
p
o
a
m
p
ietastatic involvement on STIR sagittal image (large arrow) (b) in
how metastatic involvement in L3 vertebra conﬁrmed by bone bio
ound  a  higher  ratio  of  87.9%.  While  there  is  no  signiﬁcant
orrelation  between  the  reduction  of  pain  and  cement  leak-
ge  or  amount,  serious  complications  are  related  to  cement
eakage  [24].  Alvarez  et  al.  [11]  did  not  observe  serious
omplications  in  patients  with  vertebral  metastasis  after
V,  but  they  reported  cement  leakage  in  12  of  27  verte-
ras  (44.4%).  Mikami  et  al.  [13]  detected  cement  leakage  in
9%  of  69  patients  with  vertebral  metastasis.  Complications
ther  than  these  are  vertebral  transverse  process  or  pedicle
racture,  paravertebral  hematoma,  epidural  abscess,  pneu-
othorax,  cerebrospinal  ﬂuid  leakage,  seizure  because  of
versedation  or  respiratory  arrest  and  death  [20]. In  our
tudy,  PMMA  leakage  was  present  in  a  total  of  43  verte-
ras  (45.3%)  (intradiscal  leakage  in  20  vertebras  [21.1%],
eakage  into  the  epidural  or  paravertebral  veins  in  20  verte-
ras  [21.1%]  and  leakage  into  both  disc  and  the  epidural  or
v
a
w
o-year-old woman with primary colon malignancy before PV. X-rays
fter PV (c, d).
aravertebral  veins  in  3  vertebras  [3.1%]).  But  no  serious
omplications  were  observed  in  our  patients.
BK,  RF  kyphoplasty,  percutaneous  ablation  (radiofre-
uency  or  cryotherapy)  and  plasma-mediated  radiofre-
uency  ablation  (coblation)  can  be  used  to  treat  vertebral
ractures  in  addition  to  PV.  Surgical  vertebral  body  cemento-
lasty  can  be  an  alternative  method  for  palliative  treatment
f  patients  who  are  not  suitable  for  PV  [25]. PV  and  BK
re  the  most  frequently  used  percutaneous  interventional
ethods  for  vertebral  compression  fractures.  RF  kypho-
lasty  is  a  technique  approved  in  the  USA  and  Germany
n  2007  and  2009,  respectively.  With  this  technique,  ultra-
iscous  cement  activated  by  ex-vitro  radiofrequency  is
pplied  to  the  vertebral  body  in  a constant  and  controlled
ay.  Thus,  destruction  of  the  spongy  microarchitecture
f  the  vertebral  body  is  minimized.  Röllinghoff  et  al.
tebr
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[Effectiveness  of  percutaneous  vertebroplasty  in  cases  of  ver
provided  fast  and  permanent  improvement  in  treatment  of
30  osteoporotic  vertebral  fractures  by  RF  kyphoplasty  [26].
Deschampes  et  al.  successfully  treated  75%  of  vertebral
metastases  smaller  than  3  cm  with  percutaneous  ablation
(radiofrequency)  [9].  Coblation  is  the  process  of  giving
radiofrequency  at  relatively  low  temperatures  (40—70 ◦C)
into  the  targeted  tissue  to  dissolve  molecular  bonds,  make  a
cavity  and  ﬁlling  the  cavity  with  PMMA.  Coblation  is  an  effec-
tive  and  reliable  method  used  in  high-risk  patients  who  have
excessive  pain.  Prologo  et  al.  provided  fast  improvement  in
14  of  15  patients  who  had  painful  vertebral  metastases  [27].
There  are  some  limitations  of  our  study.  First,  it  is  a  ret-
rospective  study  with  no  control  group.  Second,  most  of
patients  had  no  long-term  follow-up  because  of  their  pri-
mary  malignancies.  Third,  on  follow-up,  some  patients  could
only  be  reached  by  phone.  Face  to  face  communication
could  be  more  effective  than  speaking  on  the  phone.  Fourth,
VAS  scores  could  be  assessed  at  a  maximum  of  3  months  after
the  procedure  because  some  patients  did  not  come  to  the
control  examination  and  could  not  be  reached  by  phone.
Conclusion
PV  is  a  simple,  effective,  reliable,  easy  to  perform  and
minimally  invasive  procedure  in  patients  with  vertebral
metastases,  who  have  excessive  pain  and/or  surgery  has
great  risks.
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